- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SUN PHARMACEUTICAL INDUSTRIES LIMITED (pharmaceuticals)
- SUN PHARMACEUTICAL INDUSTRIES LIMITED Financial Data
Sun Pharma Fact Sheet 
(SUNP)
Here is the latest financial fact sheet of Sun Pharma. For more details, see the Sun Pharma quarterly results and Sun Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
SUN PHARMA Price History
| % ch | % | -0.7 |
| No. of shares | m | 2,406.75 |
| % ch week | % | -1.5 |
| % ch 1-mth | % | -0.7 |
| % ch 12-mth | % | -22.9 |
| 52 week H/L | Rs | 659.9/433.2 |
SUN PHARMA Financials
| No. of Mths Year Ending |
12 Mar-13* |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
5-Yr Chart Click to enlarge
|
|---|
| SUN PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 848 | 653 | 1,074 | 1,201 | 842 | |
| Low | Rs | 554 | 493 | 570 | 706 | 572 | |
| Sales per share (Unadj.) | Rs | 109.1 | 77.6 | 132.3 | 118.4 | 131.6 | |
| Earnings per share (Unadj.) | Rs | 28.8 | 15.2 | 21.9 | 23.5 | 32.7 | |
| Diluted earnings per share | Rs | 12.4 | 13.1 | 18.9 | 23.5 | 32.6 | |
| Cash flow per share (Unadj.) | Rs | 32.1 | 17.1 | 27.7 | 27.8 | 38.0 | |
| Dividends per share (Unadj.) | Rs | 5.00 | 1.50 | 3.00 | 1.00 | 3.50 | |
| Adj. dividends per share | Rs | 2.15 | 1.29 | 2.58 | 1.00 | 3.49 | |
| Dividend yield (eoy) | % | 0.7 | 0.3 | 0.4 | 0.1 | 0.5 | |
| Book value per share (Unadj.) | Rs | 144.7 | 89.4 | 135.2 | 137.1 | 152.7 | |
| Adj. book value per share | Rs | 62.3 | 77.0 | 116.4 | 137.0 | 152.2 | |
| Shares outstanding (eoy) | m | 1,035.58 | 2,071.16 | 2,071.16 | 2,406.60 | 2,399.26 | |
| Bonus/Rights/Conversions | - | B1:1 | - | - | - | ||
| Price / Sales ratio | x | 6.4 | 7.4 | 6.2 | 8.1 | 5.4 | |
| Avg P/E ratio | x | 24.3 | 37.8 | 37.5 | 40.6 | 21.6 | |
| P/CF ratio (eoy) | x | 21.9 | 33.4 | 29.7 | 34.3 | 18.6 | |
| Price / Book Value ratio | x | 4.8 | 6.4 | 6.1 | 7.0 | 4.6 | |
| Dividend payout | % | 17.4 | 9.9 | 13.7 | 4.3 | 10.7 | |
| Avg Mkt Cap | Rs m | 725,942 | 1,186,775 | 1,703,011 | 2,294,813 | 1,696,877 | |
| No. of employees | `000 | 14.0 | 14.0 | NA | 14.7 | 17.5 | |
| Total wages/salary | Rs m | 15,345 | 20,744 | 45,026 | 47,723 | 49,023 | |
| Avg. sales/employee | Rs Th | 8,071.3 | 11,486.0 | NM | 19,317.2 | 18,028.3 | |
| Avg. wages/employee | Rs Th | 1,096.1 | 1,481.7 | NM | 3,236.1 | 2,798.8 | |
| Avg. net profit/employee | Rs Th | 2,130.8 | 2,243.9 | NM | 3,836.9 | 4,479.5 | |
| SUN PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 112,999 | 160,804 | 273,920 | 284,870 | 315,784 | |
| Other income | Rs m | 2,763 | 2,647 | 5,477 | 6,583 | 6,232 | |
| Total revenues | Rs m | 115,761 | 163,451 | 279,397 | 291,453 | 322,016 | |
| Gross profit | Rs m | 48,962 | 72,873 | 78,667 | 81,583 | 100,893 | |
| Depreciation | Rs m | 3,362 | 4,092 | 11,947 | 10,375 | 12,648 | |
| Interest | Rs m | 432 | 442 | 5,790 | 5,232 | 3,998 | |
| Profit before tax | Rs m | 47,932 | 70,986 | 66,407 | 72,558 | 90,479 | |
| Minority Interest | Rs m | -4,863 | -7,375 | -9,363 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | -126 | 15 | 99 | |
| Extraordinary Inc (Exp) | Rs m | -4,783 | -25,174 | -2,378 | -6,852 | 0 | |
| Tax | Rs m | 8,456 | 7,022 | 9,147 | 9,138 | 12,116 | |
| Profit after tax | Rs m | 29,831 | 31,415 | 45,394 | 56,583 | 78,462 | |
| Gross profit margin | % | 43.3 | 45.3 | 28.7 | 28.6 | 31.9 | |
| Effective tax rate | % | 17.6 | 9.9 | 13.8 | 12.6 | 13.4 | |
| Net profit margin | % | 26.4 | 19.5 | 16.6 | 19.9 | 24.8 | |
| SUN PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 115,030 | 186,865 | 288,782 | 299,413 | 329,537 | |
| Current liabilities | Rs m | 28,413 | 59,896 | 153,294 | 131,440 | 178,870 | |
| Net working cap to sales | % | 76.7 | 79.0 | 49.5 | 59.0 | 47.7 | |
| Current ratio | x | 4.0 | 3.1 | 1.9 | 2.3 | 1.8 | |
| Inventory Days | Days | 83 | 71 | 76 | 82 | 79 | |
| Debtors Days | Days | 78 | 50 | 68 | 87 | 83 | |
| Net fixed assets | Rs m | 50,771 | 58,242 | 151,694 | 180,477 | 204,766 | |
| Share capital | Rs m | 1,036 | 2,071 | 2,071 | 2,407 | 2,399 | |
| "Free" reserves | Rs m | 136,274 | 163,019 | 278,009 | 327,418 | 363,997 | |
| Net worth | Rs m | 149,897 | 185,250 | 280,080 | 329,825 | 366,397 | |
| Long term debt | Rs m | 1,153 | 487 | 13,598 | 31,103 | 14,361 | |
| Total assets | Rs m | 205,827 | 293,708 | 501,601 | 555,303 | 614,102 | |
| Interest coverage | x | 112.1 | 161.6 | 12.5 | 14.9 | 23.6 | |
| Debt to equity ratio | x | 0 | 0 | 0 | 0.1 | 0 | |
| Sales to assets ratio | x | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |
| Return on assets | % | 14.7 | 10.8 | 10.2 | 11.1 | 13.4 | |
| Return on equity | % | 19.9 | 17.0 | 16.2 | 17.2 | 21.4 | |
| Return on capital | % | 25.6 | 20.9 | 20.5 | 19.7 | 24.8 | |
| Exports to sales | % | 17.0 | 14.1 | 16.9 | 13.9 | 0 | |
| Imports to sales | % | 4.7 | 3.6 | 4.5 | 3.1 | 0 | |
| Exports (fob) | Rs m | 19,238 | 22,713 | 46,235 | 39,572 | 0 | |
| Imports (cif) | Rs m | 5,353 | 5,779 | 12,229 | 8,882 | 0 | |
| Fx inflow | Rs m | 19,615 | 23,168 | 48,706 | 42,171 | 44,118 | |
| Fx outflow | Rs m | 7,877 | 12,629 | 25,564 | 21,583 | 24,484 | |
| Net fx | Rs m | 11,739 | 10,539 | 23,142 | 20,588 | 19,634 | |
| SUN PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 33,566 | 39,592 | 56,157 | 66,859 | 70,822 | |
| From Investments | Rs m | -26,351 | -23,668 | -28,657 | -43,716 | -42,216 | |
| From Financial Activity | Rs m | -6,650 | 5,066 | -11,865 | -18,885 | -22,854 | |
| Net Cashflow | Rs m | 565 | 20,990 | 15,635 | 8,482 | 6,107 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Israel Makov | COMP SEC: Sunil R. Ajmera | YEAR OF INC: 1993 | BSE CODE: 524715 | FV (Rs): 1 | DIV YIELD (%): 0.7 |
More Pharmaceuticals Company Fact Sheets: J.B.CHEMICALS GSK PHARMA CIPLA ORCHID PHARMA LTD GLENMARK PHARMA
Compare SUN PHARMA With: J.B.CHEMICALS GSK PHARMA CIPLA ORCHID PHARMA LTD GLENMARK PHARMA
Compare SUN PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices End Flat; IT Sector Ends 4.8% Higher(Closing)
After opening their day on a negative note, Indian share markets witnessed choppy trades and ended their session on a flat note.
Views on news
Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)
Nov 20, 2017The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)
May 30, 2017US markets decline while other geographies grow in the quarter.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
Why India is Short of Cash Again(Vivek Kaul's Diary)
Apr 19, 2018It is basically a supply problem with not enough currency going around in the financial system.
If Your Broker Calls You, Bang the Phone Down!(Smart Contrarian)
Apr 10, 2018I'm going to tell you certain things about the inner workings of the industry so that you know why his advice is likely to be at best junk, and at worst dangerous.
How to Pick Great Stocks with Rajeev Thakkar(The 5 Minute Wrapup)
Apr 9, 2018Rajeev Thakkar tells us how teachings from Vipassana can help you became a better investor.
How Small Caps Can Change the Way You Eat, Sleep, and Drive(Sector Info)
Apr 11, 2018How you can increase your odds of seizing multibagger stocks and rake in the moolah by investing in small cap stocks.
This is How a Smart Robo-Advisor can Help You Chart Your Asset Allocation...(Outside View)
Apr 16, 2018PersonalFN explains how a dependable robo-advisory platform can help you create your personalized asset allocation plan
More|
| |
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.